Verition Fund Management
AAPG

Verition Fund Management’s Ascentage Pharma AAPG Stock Holding History

Verition Fund Management’s Portfolio AAPG Stock Details AAPG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,922
Closed -$218K – 3935
2025
Q1 		$218K Buy
+9,922
New +$188K ﹤0.01% 3022

Other funds holding AAPG

PD
Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return
NIM
NEOS Investment Management Westport, Connecticut $19.8B AUM 31.12% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
XC
XY Capital Central, Hong Kong $101M AUM 1.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIA
Bell Investment Advisors Oakland, California $681M AUM 18.36% 1-Year Est. Return

Verition Fund Management's AAPG Position: Q2 2025 in Review

Verition Fund Management sold out of Ascentage Pharma (AAPG) in Q2 2025, closing a stake of 9,922 shares — an estimated $218K sold.

Verition Fund Management first reported a position in AAPG in Q1 2025 and held it in 1 quarter. The position peaked at $218K in Q1 2025. 12 funds tracked by Wall St. Rank hold AAPG as of Q2 2025.

  • Verition Fund Management reported no remaining Ascentage Pharma position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 9,922 Ascentage Pharma shares in Q2 2025, an estimated $218K.
  • Verition Fund Management first reported a position in Ascentage Pharma in Q1 2025 and held it in 1 quarter.
  • Verition Fund Management's Ascentage Pharma position peaked at $218K in Q1 2025.
  • 12 funds tracked by Wall St. Rank held Ascentage Pharma as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.